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Abstract
A first research development progress report of the Chromosome 19 Consortium with members
from Sweden, Norway, Spain, USA, China and India, a part of the Chromosome-Centric Human
Proteome Project (C-HPP) global initiative is presented (http://www.c-hpp.org). From the
chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted
using a sub-set with 125 isotope-labeled peptides. We applied an annotation strategy with triple
quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data
within, and in-between these instrumental set-ups. LC-MS conditions were outlined by multiplex
assay developments, followed by MRM assay developments. SRM was applied to biobank
samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer
patients. The antibody production has been initiated for more than 1200 genes from the entire
chromosome 19, and the progress developments are presented. We developed a dedicated
transcript microarray, to serve as the mRNA identifier by screening cancer cell lines. NAPPA
protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip,
dedicated to 90 proteins, as the first development delivery. We have introduced an IT-
infrastructure utilizing a LIMS system that serves as the key interface for the research teams in
order to share and explore data generated within the project. The cross-site data repository will
form the basis for sample processing, including biological samples, as well as patient samples
from national Biobanks.
Keywords
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Human Disease
1. INTRODUCTION
In September 2010, during the Human Proteome Organization’s (HUPO) annual conference
in Sydney, Australia, the world’s proteomics community officially launched the Human
Proteome Project (HPP), at which the chromosome 19 outline and strategy was approved.
The goals of the HPP are to map and characterize human proteins in their biological context,
as well as to develop novel tools and reagents that the scientific community and, more
specifically, the proteomics community can use to promote their understanding in the
field 1–4. This activity forms an ambitious attempt to characterize the expression, abundance
and localization of at least one representative isoform of each of the 20,300-odd protein-
coding genes in the human genome (http://hupo.org/research/hpp/).
The HPP has been conceived as a multi-center, multi-technology coordinated effort, and the
Chromosome 19 Consortium represents one such dedicated resource. As part of the HPP, the
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Chromosome 19 Consortium will investigate multiple levels of biology on different but
complementary analysis platforms, to provide a genome-wide human protein resource
consisting of a proteome “parts list”, the protein distribution atlas, and detailed maps of
protein molecular pathways, interactions, and networks 5.
Currently most drug developments are based on the protein target-based concept, where
these proteins have a key function in biological processes active in disease development 6.
By alteration of this function, with a pharmaceutically active drug, the disease process can
be altered, and in the best case stopped, thereby limiting disease morbidity in the patient.
The development steps of this drug development process will heavily rely on the basic and
detailed knowledge of:
• The target protein sequence(s)
• The target protein forms being expressed in disease and health
• Target protein modifications – post translational modifications
• Target expression variation throughout the disease evolvement
The need for protein assays in all of these drug development steps is crucial, and is directly
linked to the success of novel drug introductions to the healthcare market. This will make
the annotation and protein assay developments in the C-HPP initiative an important science
task and challenge to complete.
The current Chromosome 19 Consortium multi-center study presents data and platform
developments with a synergistic and complementary output, by combining several
complementary methods in one framework. The aim of this study is to outline a
complementary platform development, comprising transcript and protein arrays, as well as
MRM quantitation pilot study data and the antibody resource capability. The goal of the
consortium is also to provide a uniform IT-infrastructure that allows inter and intra-
laboratory samples and data to be handled and processed throughout continents. The
Nautilus LIMS provides a sample, and data safety in terns of a documentative archiving
system that is traceable and that can give evidence of details that relates to the experimental
events executed.
2. EXPERIMENTAL
2.1. CLINICAL SAMPLES
Blood plasma from prostate cancer patients (n=17) was obtained from the Malmö University
Hospital, Sweden. Ethical approval was granted by the Lund University (approval number
LU-532-03). The samples were first depleted for the seven most abundant proteins using a
MARS Hu-7 spin column following the manufacturer’s instructions (Agilent Technologies)
and then were reduced and alkylated. The start volume for the processed blood plasma was
10 μL and the final restored volume was 50 μL 5% acetonitrile (ACN) with 0.1% formic
acid. Tryptic digestion was performed on both seminal and blood plasma samples by adding
sequencing grade trypsin (Promega) at 1:100 molar ratio calculated and incubating at 37°C
overnight on a block heater shaking at 900 rpm. The reaction was stopped by addition of 10
μL of 1% formic acid. The resulting protein digests were dried on speed vacuum
centrifugation and re-suspended with 100 μL of 5% ACN prior injection. The samples were
stored at −20°C until analysis. Internal standard peptides (AQUA, Thermo Scientific, Ulm,
Germany) were used as quantification peptides for prostate specific antigen (PSA). They
were isotope labeled with 15N and 13C in lysine (+8 in mass) and arginine (+10 in mass).
These heavy peptides were spiked into the samples at known concentrations and the ratio
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between endogenous and heavy peptide was used to calculate the concentration in the
samples.
Blood serum from a colon cancer patient was obtained from the University Hospital in
Salamanca, Spain. Ethical approval was provided by ethical committee of Cancer Research
Center and Hospital Universotario de Salamanca, reference FIS11/02114.
2.2. MASS SPECTROMETRIC ANALYSIS OF THE SYNTHETIC PEPTIDE STANDARDS
In order to evaluate the quality and usability of the synthetic peptides, we tested isotope
labeled synthetic peptides with two different qualities using different mass spectrometric
platforms. 95 randomly selected peptides from PEPotec SRM Peptide Library (crude peptide
purity) and 31 AQUA QuantPro (peptide purity higher than 97%, concentration precision
equal or better than ±25%) (Thermo Scientific) were analyzed at three sites and the data
were shared and compared.
nLC-MS/MS analysis—We took 1 μL of each crude peptide stock solution (95 in total)
and mixed them. Then we dried down the sample and re-suspended the 95 peptides in 10
μL. One μL of this solution was injected into the Orbitrap Velos Pro and analyzed during a
60-minute gradient. Data analysis was performed against the human SwissProt database by
using Mascot search engine. Precursor and fragment mass tolerance were set to 15 ppm and
0.7 Da, respectively. Oxidation at methionine was used as dynamic modification;
carbamidomethylation on cysteine residue, heavy labeled C-terminal K and R were used as
static modifications. The filters allowed 1% false discovery rate.
MALDI-MS analysis—Crude peptides, supplied by Thermo Scientific as concentrated
solutions, were analyzed by MALDI-TOF MS (Bruker Ultraflextreme, Bremen, Germany)
in positive ion and reflectron mode using an automated acquisition method. Briefly, 0.5 μL
of crude peptides were deposited on a MALDI target that had pre-spotted CHCA matrix
(Bruker). Samples were allowed to dry and spectra from 500 laser shots were acquired.
Spectra were processed and compared to the theoretical mass of the heavy peptide
component of each sample.
MRM assay development—Three mixtures were created from the crude peptides, ca. 30
peptides in each mixture with a concentration of 50 fmol/μL and one mixture from the
QuantPro peptides with a concentration of 10 fmol/μL of each peptide. The transition lists
were created in Skyline v1.2 software (MacCoss Lab). Primarily, high numbers of
transitions, all possible y-ion series that matches the criteria (from m/z > precursor-2 to last
ion-2, precursor m/z exclusion window: 20 Th), were selected for each peptide at both 2+
and 3+ charge states. The peptide mixtures were analyzed by nanoLC-MS/MS using a TSQ
Vantage triple quadrupole mass spectrometer equipped with an Easy n-LC II pump (Thermo
Scientific, Waltham, MA). The samples were injected onto an Easy C18-A1 pre-column
(Thermo Scientific, Waltham, MA), and following on-line desalting and concentration the
tryptic peptides were separated on a 75 μm x 150 mm fused silica column packed with
ReproSil C18 (3 μm, 120 Å from Dr. Maisch GmbH, Germany). Separations were
performed in a 45-min linear gradient from 10 to 35% acetonitrile containing 0.1% formic
acid; at the flow rate of 300 nL/min. The MS analysis was conducted in positive ion mode
with the spray voltage and declustering potential were set to 1750 V and 0, respectively. The
transfer capillary temperature was set to 270°C and tuned S-lens value was used. SRM
transitions were acquired in Q1 and Q3 operated at unit resolution (0.7 FWHM), the
collision gas pressure in Q2 was set to 1.2 mTorr. The cycle time was 2.5 s in the non-
scheduled methods and 1.5 s in the scheduled methods. The best transitions (3-5 per
precursor) were selected by manual inspection of the data in Skyline and scheduled
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transition lists were created for the final assays. The selected transitions were tested in real
matrix also by spiking the heavy peptide mixtures into human plasma digests. From the
peptides that provided bad or no signals in the first round, a new mixture with higher
concentration was created and the complete workflow was repeated with the addition of a
MALDI-MS analysis of these peptides.
2.3. mRNA MICROARRAY
Target preparation - RNA extraction and labeling, and microarray
hybridization—Total RNA extracted and purified from defined glioma-derived stem cell
lines was used as the substrate for RNA amplification and labeling using a procedure based
on the Eberwine protocol 7. Specifically, reverse transcription of 5 μg RNA primed with an
oligo(dT) primer bearing a T7 promoter is followed by in vitro transcription in the presence
of amino-allyl dUTP. We used universal human reference RNA in our analyses and treated
identical aliquots concurrently with the tissue samples. The Cy5-labeled (experimental) and
purified Cy3-labeled (reference) amplified RNA (aRNA) targets were combined in an
optimized hybridization solution, subsequently denatured and hybridized in a humidified
hybridization chamber at 46°C for 16 h. Following sequential high-stringency washes,
individual Cy3 and Cy5 fluorescence hybridization to each spot on the microarray was
quantitated by a high resolution confocal laser scanner.
2.4. QUANTITATIVE PROTEOMIC ANALYSIS OF 46 GLIOMA CANCER STEM CELL LINES
The experiments were performed twice from single culture dishes of Glioma cancer stem
cell (GSC) lines, exactly as described in 8. Following cell lysis, protein concentrations were
measured by the Bradford assay.
TMT tagging—Each sample (100 μg protein) was adjusted to give a final volume of 100
μL with 45 μL 200 mM tetraethylammonium bromide (TEAB) and ultrapure water, as
necessary. Five microliters of 200 mM tris(2-carboxyethyl)phosphine (TCEP) buffered with
TEAB was added to each sample and incubated at 55°C for 1 h. Five microliters of 375 mM
iodoacetamide (buffered with TEAB) was added and incubated in the dark for 30 min.
Proteins were precipitated in 440 μL of ice-cold acetone for 2 h at −20°C. Samples were
centrifuged at 10,000 g for 30 min at 4°C. The supernatants were discarded. Pellets were air-
dried and re-suspended in 12.5 μL of 8 M urea. Trypsin (10 μg in 87.5 μL of TEAB buffer)
was added, and the samples incubated for 24 h at 37°C. Five single 100 μg GSC extracts at a
time were tagged by use of a Thermo Scientific TMTsixplex Isobaric Mass Tagging Kit
(Thermo Fisher Scientific, Rockford, IL) according to the manufacturer’s instructions. A
100-μg sample of a mixture of four GSC line digests was also tagged in order to provide a
reference channel. The chemically tagged samples were mixed and stored at −80°C.
HILIC fractionation—Samples were desalted, dried and reconstituted in 1.3 mL of 85%
ACN/ 56 mM formic acid (aqueous), pH 3.0. Samples were fractionated by use of a
hydrophilic interaction chromatography column (HILIC, PolyLC Polyhydroxyethyl A,
PolyLC Inc., Columbia, MD), 200 x 4.6 mm, particle size 5 μm. Buffer A was 85%
acetonitrile (ACN)/ 56 mM formic acid, pH 3.0, and buffer B was 8.5 mM ammonium
formate/56 mM formic acid, pH 3.0. Twenty-four 1 mL fractions were collected.
LC-MS/MS analysis—Fractions were dried and reconstituted in 5% (v/v) ACN and 1%
(v/v) formic acid in water and injected through a UPLC system equipped with an
autoinjector (Proxeon EASY nLC) on a C18 capillary column (New Objective). The
peptides were separated in a 180 min gradient and analyzed in positive ion mode. The LTQ-
Orbitrap Elite system was operated in a top 5 configuration with monoisotopic precursor
selection enabled, and +1 and unassigned charge states rejected. Fragmentation of ions was
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achieved by HCD fragmentation using an isolation window of 4.5, collision energy 45 and
activation time of 30 ms.
Data analysis—LC-MS/MS data analysis was performed with Proteome Discoverer
(Thermo Scientific) and combined MASCOT (Matrix Science) and Sequest searches of the
human Swiss-Prot database. At least two peptides were required per protein. The filters
allowed a 95% confidence level per protein identification (5% false discovery rate). Protein
ratios were obtained for a given GSC line extract relative to the external GSC mixed
standard. Through a “ratio of ratios” approach 9, relative protein expression between any of
the GSC lines can be inferred.
3. RESULTS AND DISCUSSION
3.1. CHROMOSOME 19 WORKFLOW AND STRATEGY
The Chromosome 19 research team has worked out a detailed workplan whereby specific
milestones of platform validation, data acquisition and analysis will be obtained throughout
the project period (see Figure 1). Our strategy encompasses both observational and targeted
approaches, quality control of data sets, data storage as well as data sharing. In the
observational approach applied to ongoing proteomic studies, the presence of mRNA
encoded by chromosome 19 genes is measured in cells and tissues. In quantitative proteomic
and phosphoproteomic assays, relative quantitation by use of isobaric tagging reagents
(TMT6™, Thermo-Fisher Scientific) enables assignment of chromosome 19 protein
functions in disease and response to drug treatment.
The C19C team is currently applying a targeted approach where we develop and outline
validated assays with both mass spectrometry, and antibody based platforms in order to
fulfill the annotation of all coded proteins. Simultaneously, we apply an observational
approach, where we make protein discovery and identification, as well as characterization of
antibodies in Biological and Diseased samples, i.e., the B/D-approach. In order to fulfill the
goals of the project the Consortium has established a toolbox resource strategy outlined in
Figure 1. This multipronged approach constitutes: synthesized peptide library to be used
within the mass spectrometric platforms, antibody library for protein assessment and disease
correlation, protein and transcript microarray platforms and IT infrastructure that
interconnects the data flow and analysis output within the consortium.
3.2. BIOINFORMATIC ANNOTATIONS ON CHROMOSOME 19
3.2.1. Genomic Characteristics of Chromosome 19—Chromosome 19 is one of the
22 autosomal chromosomes in humans. Chromosome 19 spans about 64 million base pairs;
this high number represents more than 2 percent of the total DNA in human cells. Because
researchers use different approaches to predict the number of genes on each chromosome,
the estimated number of genes varies.
In addition, chromosome 19 has the highest gene density of all human chromosomes. It is
more than twice the genome-wide average. The characteristics of chromosome 19 also
provide evidence of large clusteres of gene families, that corresponds to high G + C content,
CpG islands and density of repetitive DNA indicate a chromosome rich in biological and
evolutionary significance 10. Chromosome 19 is also unique in its density of repeat
sequences. It was found that close to 55% of this chromosome consists of repetitive
elements. Chromosomes 6, 7, 14, 20, 21 and 22 all have repeat contents ranging from 40%
to 46%; the genome average is 44.8%. The characteristics of chromosome 19 (Table 1) are
due mainly to an unusually high content of short interspersed nuclear elements (SINEs) 10.
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Chromosome 19 likely contains about 1,400 protein-coded genes, based on the database
searches in UniProt and neXtProt (see Figure 2AB). More than 60% of chromosome 19
proteins have already been identified at expression level, whereas the about 36% is known
from transcript data only and an additional small fraction (<4%) is predicted or unknown.
Proteins coded on chromosome 19 are represented in all cellular compartments, mostly in
nucleus, cytoplasm and membranes as shown in Figure 2C. Similarly, these proteins
participate in a wide array of biological functions, including transcription, regulation and
transport as the Protein Information and Knowledge Exchange (PIKE - http://
proteo.cnb.csic.es/pike) has revealed (see Figure 2D). The number of genes clustered on
chromosome 19 has been proven to have disease links, such as the kallikreins linked to
prostate cancer, the zinc finger proteins linked to inflammatory diseases, as well as the
apolipoproteins’ (C2 and E) functions that relate to cardiovascular diseases. The data and
output generated within C19, will apply standards for mass spectrometry based
proteomics 11–14.
3.2.2. Chromosome 19 Peptide Library—Selected target peptides for each
chromosome 19 protein is a key requisite for our research teams in order to build assay
platforms as well as verify expression levels of proteins in patient samples from biobank
archives. This, in order to manage an efficient annotation of such a large number of proteins,
and to outline the disease association and function, this peptide library is mandatory. We
apply a strategy where we utilize target peptides to known proteins, as well as unknown
proteins, as a tool function and resource to our research teams. The collection of peptides
derived from proteins coded on chromosome 19 has been gathered, containing 6159
sequences. The corresponding number of proteins is 1374, i.e., 75% of which is represented
by 2–6 sequences/protein, providing multiple choices for selecting signature peptides.
Furthermore, the library has 241 sequences that are specific to isoforms of 182 proteins. Out
of these, 101 peptides are specific to single-nucleotide polymorphism, which is also
reflected in the protein sequence as an amino acid alteration. This becomes a unique
possibility for the C19C to develop assays for identification of proteins coded on
chromosome 19.
In order to develop specific assays for protein identification and quantification, we have
recently purchased the Human SRM ATLAS Peptide Library (Thermo Scientific),
developed at the Institute for System Biology (ISB), Seattle, WA, USA. The library contains
93,140 non-labeled, synthetic peptide sequences with crude quality, which correspond to
24,524 unique accession numbers. More information about the specification is available at
the following webpage, www.thermoscientific.com/SRM-ATLAS. We have identified 6159
peptides in the Atlas that are uniquely associated with protein consensus sequences coded on
chromosome 19 (Supplementary Table 1). Most of the chromosome 19 proteins have at least
one, but usually two to six unique peptides in the Atlas, and only 46 proteins (based on
search in UniProt DB) are not represented in our peptide repository. Our goal it to employ
these Human SRM Atlas sequences to develop specific quantitative mass spectrometry
assays. Perhaps the most challenging issue will be the detection and quantification of the
almost 40% chromosome 19 proteins that have never been detected at the protein level.
3.3. PILOT STUDY – TARGETED 126 ISOTOPE LABELED PEPTIDES
Selecting a specific peptide library for a given chromosome is a real challenge, as it implies
that in silico predictions are made as the basis for target peptide selections where in many
cases, they do not hold any experimental evidence. Another challenge is the homology of
peptide repeats in protein classes and families. It is also evident that diseases do not link to
single chromosome only; rather it has multiple chromosome assignment. As the target
peptides are the key link to biology, and disease signatures appearing in clinical samples, it
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is mandatory to fulfill the consortium objective to build a peptide library that holds the
highest value. We have given high priority to establish and provide an extensive human
peptide library covering most of the 20,300 proteins in 22 autosomal and YX chromosomes,
and select the targeted 6159 peptides from chromosome 19, for sequences and details, see
Supplement Table 1.
3.3.1. MS Survey of Peptide Library Samples—A dedicated peptide library is a key
tool in our C-HPP activities, however in order to be able to follow up with quantitative data
in biobank studies of protein expression, isotope labeled peptides are mandatory. We
initiated an experimental study with isotope labeled peptides that represented chromosome
19 target peptides as well as peptides from many other chromosomes. The quality of the
crude peptides, used in this pilot study is the same as in the SRM Atlas, except that these
peptides were synthesized with a heavy labeled C-terminal Lysine or Arginine. Isotope
labeled crude peptides are equally valid during the MRM assay development as the normally
used non-labeled peptides, with additional benefits, such as the validation of the transitions
in spiked biological samples and the possibility of relative quantitation.
We utilized three different mass spectrometric platforms within this pilot study analyzing
the subset of 126 peptides (shown in Table 2). In order to evaluate our planned targeted
workflow, illustrated on Figure 3, we tested isotope labeled synthetic peptides with two
different qualities. 95 randomly selected peptides from PEPotec SRM Peptide Library
(crude peptide purity) and 31 AQUA QuantPro (peptide purity higher than 97%,
concentration precision equal or better than ±25%) (Thermo Scientific) were analyzed
(shown in Table 2).
We performed MALDI-MS analysis, nLC-MS/MS analysis in order to get sequence
identification and nLC-MRM/MS analysis to provide transition lists for each peptide. Data
analyses were made at each site and then the records were shared within C19C to create a
comprehensive report.
The higher quality peptides, QuantPro (peptide purity higher than 97%), were analyzed by
nanoLC-MRM/MS, and only 4 out of the 31 peptides did not give a satisfactory signal in the
MRM assay (Figure 4A). Two of them were highly hydrophobic (hydrophobicity higher
than 45) and the other two were short, hydrophilic sequences. These four peptides would not
be predicted to perform well as SRM standards. These findings underscore the importance
of the use of intelligent design of standards through predictive software tools.
The 95 crude peptides were analyzed in all the three MS platforms. Satisfactory spectra were
obtained from each case in the MALD-MS analysis, but the intensities of the heavy peptides
were highly variable between samples. 20% of the peptides were not detectable using a
MALDI-TOF instrument. The remaining peptides were divided into 3 groups based on the
relation between the heavy peptide signal and the background (Table 2B and Figure 4B).
More than 50% of the full set gave good, i.e., appropriate target peptide signal but in a
complex background, or excellent responses, i.e., the target peptide signal is the major
component in the spectrum. We could confirm 72 peptide sequences out of the 95 using
nanoLC-MS/MS analysis together with database search, and only 24% of the peptides could
not provide good quality MS/MS spectra. The crude peptides were divided into three groups
for the MRM analysis, and we followed a two-round workflow, illustrated on Figure 3. We
found that 85% of the crude peptides gave appreciable signal in the first round, which could
be increased to 95% by increasing the concentration in the second round of analysis (Figure
4B and Table 2B). The five best transitions were selected for each precursor ion, and we
kept both the doubly and the triply charged precursor ions, when the signals were equally
good. We compared the experimental fragment ion distribution with the spectral library
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data, when it was available, and the dotp values were 0.9 or higher in most cases. Since
many of the randomly selected sequences contained methionine we used methionine
oxidation as variable modification, and followed the changed precursor and fragment ions,
as well. We provided the collected MRM data in table format, containing the 5 best
transitions for each precursor, with fragment ion ranks, collision energies, retention times,
peak areas and injected volumes (Supplementary Table 2). We created three categories
based on the quality of the acquired MRM signals, as demonstrated on Figure 5 with some
representative examples. 24 out of the 95 peptides gave poor results, i.e., the group of
transitions was identifiable, but with really low intensities, or clear signal was only
detectable in the second round, with higher injected amounts. Nearly 50% of the peptides
provided peaks close to the expected retention times with moderate or high signal
intensities, categorized as good MRM signal; and 22 peptides represented with really high
signals, which we named the excellent category.
The transitions were further investigated in human plasma digest, as a clinical matrix. In
pooled human plasma digest we were able to detect endogenous signals correspond to three
monitored peptides (Supplementary Figure 1); in addition we could not find any matrix
interference in the selected heavy transitions. Overall we analyzed six chromosome 19
related tryptic peptides (highlighted in bold in Table 2) in the pilot study, and four of them
provided appropriate signal in the MRM assay. One peptide, IVGGWECE[K] was further
investigated in the kallikrein assay analyzing the linearity range and LOQ.
The results obtained by these three MS platforms were in agreement in most cases, and it is
quite obvious, that the most sensitive approach is the targeted LC-MRM/MS analysis.
Despite the low purity of the crude peptides as proved by the MALDI-MS determinations,
the peptides were found to be highly suitable for the development of MRM assays.
By using the workflow illustrated in Figure 3 of the pilot study analyzing randomly selected
peptide sequences from the Human SRM ATLAS, we can confirm the statement of Dr.
Robert Moritz that approximately 90% of the ATLAS peptides are usable in multiplex
MRM assay developments.
3.4. SWEDISH BIOBANK CANCER PATIENT SAMPLES
A selection of peptides was chosen to provide expression quantitations on kallikrein 3
(prostate specific antigen – PSA), a marker of prostate cancer. These data were generated
from prostate cancer patients, where the plasma samples were retrieved from a local
Swedish biobank. The sample workflow, utilizing patient samples retrieved from a biobank
in Sweden is depicted in Figure 6A. In Figure 6B, the resulting MRM data are presented
with the signals of the transitions of the respective PSA sequences of the most useful target
peptides LSEPAELTDAVK and SVILLGR. Comparing PSA levels estimated by the MRM
assay and ELISA tests, we could conclude that the concordance was remarkably high by
comparing the peptides; LSEPAELTDAVK, FMLCAGR, HSQPWQVLVASR and
FLRPGDDSSHDLMLLR. Figure 6C provides structure details of PSA where the color-
coding is assigned to each tryptic peptide sequence that potentially are useful for the
identification and quantification of PSA in the prostate cancer samples from the biobank.
Due to the difference in digestion efficiency and ionization properties and furthermore due
to the low endogenous level of PSA in clinical samples, typically the peptide sequences in
the order of LSEPAELTDAVK, SVILLGR, FMLCAGR, HSQPWQVLVASR and
FLRPGDDSSHDLMLLR appeared to be useful as signature peptides. However, the
difficulties related to oxidation of methionine and tryptophan, the latter three sequences
were excluded in developing a quantification assay of PSA. Notably, the tryptic peptide of
IVGGWECEK (red color in Figure 6C) is not proteotypic as both kallikrein 2 (hK2) and
PSA share this sequence. However, this common sequence provided a combined expression
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level of hK2 and PSA, where the low abundant level of hK2 can be disregarded in patient
screening utilizing blood plasma.
3.5. ANTIBODY GENERATION
In order to annotate the presence of the chromosome 19-encoded proteins in tissues,
antibodies targeting these proteins are generated. The process includes generation of
antigens (Protein Epitope Signature Tags - PrESTs) and antibodies, analyses of selected
biosamples, validation of the results and publication of the acquired data on an open web
page (www.proteinatlas.org). The antibodies are used for immunohistochemistry (IHC)
staining of tissue to visualize the protein expression patterns and thereby render tissue and
cellular localization of proteins available, both at cellular and subcellular levels. Throughout
the different steps in the process focus is put on the final selectivity of the raised antibody 15.
The chromosome 19 team works closely with Human Protein Atlas to utilize common
resources and platforms to build future values.
According to ENSEMBL, chromosome 19 consists of almost 1400 genes and antibody
production has been initiated for more than 1200 of these (see Figure 7). These are currently
in different production modules and all will eventually be processed until antibodies are
achieved. For more than 85% of the genes, mRNA has been isolated from human RNA-
pools and the DNA have been cloned into expression vectors. For most of these genes,
PrESTs have already been produced. Antibodies have been raised against the protein
product of almost 900 genes and more than 700 of these have been validated and the
achieved expression patterns can be found on the Protein Atlas web page
(www.proteinatlas.org). So far, about 150 genes have been further processed. Two
antibodies have been produced directed to the same encoded protein and these antibodies
have been used in tissue analysis (immunohistochemistry - IHC). This strategy gives the
opportunity to compare the attained expression patterns and thereby a more accurate
comprehension of the results can be achieved.
3.6. PROTEIN MICROARRAY
Nucleic Acids Programmable Protein Arrays (NAPPA) are utilized within C19C for high-
throughput screening (HTS), validation and protein function conformations. Currently, most
established method for HTS production of recombinant proteins relies on expression and
purification in E. coli. However, not all human proteins can be accurately expressed in E.
coli. To overcome these limitations, recent efforts aimed to sequence, annotate and clone
full length open reading frames (ORFs) for several pathogens or human proteins have
become successful and many of these reagents are currently widely available
(www.dnasu.org and www.plasmid.med.harvard.edu).
Recombinant proteins from an expression library are often used and, while many can be
expressed in cellular systems, there are many other proteins (including antibodies) for which
expression can be made using cell-free expression systems from cDNA, using commercially
available in vitro systems 16. We apply an alternative approach for microarray fabrication
with cell-free protein production using in situ methods, in which proteins of different
properties are simultaneously immobilized and produced, enabling arrays to be created on
demand with very low initial concentration requirements with NAPPA, protein in situ array
(PISA), or in situ puromycin capture from mRNA arrays.
In our Chromosome 19 Consortium, NAPPA arrays have been already implemented with a
collection of cDNA around 500 human proteins encoded in chromosome 19, and sequence
validated. Currently, a subset of 90-protein NAPPA microarray has been developed in cell-
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free expression vector system. The quantitative expression levels are related to the
fluorescent readout from a colon cancer patient.
3.7. mRNA MICROARRAY
In order to address gene activity in cells and tissue, a chromosome 19 chip assay was
devised (for gene representation, see Supplementary Table 3). All tissues and cells were
analyzed for gene activity related to chromosome 19 at the Falk Center for Molecular
Therapeutics in Evanston, IL. Understanding which parts of the chromosome genome are
active in tissues in various experimental conditions can help guide us in the development of
proteomic assays to identify proteins and their isoforms in the 30% of the chromosome 19
proteome that have not yet been detected. Expression data from a pilot chromosome 19
array, which contained 192 chromosome 19-specific transcripts (chosen at random),
corroborated other focused arrays that we have designed, in that it produced approximately
65–75% measurable signals from transcripts expressed in the human GSC lines. Of
particular interest, expression of four of the seven ORF transcripts encoding as yet
unidentified proteins that were represented on this pilot array (~60%) was clearly detectable.
Based on these results, we fully expect a similar proportion of positive signals on the full
Chromosome 19 array platform, described below.
Microarray fabrication, validation, and quality control—The 1422 transcripts
comprising our chromosome 19 microarrays were compiled from the Chromosome-Centric
Human Proteome Project database (release: 2012.04 from 18Apr2012) and provided
comprehensive representation from both defined and putative transcripts (see Supplementary
Table 4). Individual 45-mer oligonucleotides complementary to these sequences were
designed and prioritized based on combining very stringent selection criteria (minimal
secondary structure, minimal homology to other genes in the available human genomic
databases, no low complexity or repeat regions, defined Tm) with a statistical ranking
algorithm 17. Control oligonucleotides representing the most traditionally accepted and
commonly utilized housekeeping genes 18 were also be similarly designed, prioritized, and
included on the array. These optimal oligonucleotides were individually synthesized in 96-
well plates utilizing standard phosphoramidite chemistry. Each oligonucleotide was capped
with a 5’-amino linker ensuring covalent attachment of only full-length, properly
synthesized oligos to epoxy-treated glass microarray slides. Microarray manufacture utilized
a robotic microarrayer to covalently link quadruplicate elements to epoxy-treated glass
slides using previously optimized parameters. Each batch was quality controlled stringently
prior to each analysis, exactly as described in 19, 20. Specifically, the dynamic range,
discrimination power, accuracy, reproducibility, and specificity of the oligonucleotide
microarrays used in these studies were evaluated by exogenous mRNA spiking
experiments 21. We used discrimination power, or the ability to discriminate authentic signal
from background at the low end of the dynamic range, to set appropriate cutoffs prior to
statistical analysis of the data (described below). Any data obtained that are below this
cutoff were excluded. The dynamic range of detection of our microarray platform, defined
as the range of transcript abundance over, which hybridization intensity was linearly
correlated, was found to be between two and three orders of magnitude in six independent
experiments. The data from our pilot chromosome 19-centric chip fell within this dynamic
range. Reproducibility levels using our microarray platform, as estimated by coefficients of
variation, are typically CV=0.09. The accuracy of the microarray results, as determined by
direct comparison to individual mRNA abundance determined by qRT-PCR analysis of the
spiked mRNA samples, routinely produced Pearson correlation coefficients of greater than
+0.92.
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Data acquisition and statistical analysis—Arrays were scanned using two lasers (633
nm and 543 nm) at 5 μm resolution at the maximal laser power that produced no saturated
spots. Data from these scans were then analyzed using the adaptive threshold method to
differentiate the spot from the background. Spot intensity was determined using median
pixel intensity. Prior to normalization, quality confidence measurements (spot diameter, spot
area, array footprint, spot circularity, signal-to-noise ratio, spot uniformity, background
uniformity, and replicate uniformity) were calculated for each scanned array to assess
overall quality and to ensure that acceptable tolerance limits are not exceeded. Spots that did
not pass stringent selection criteria were eliminated. The data from each channel were
normalized using the locally weighted scatterplot smoothing (LOWESS) curve-fitting
equation. Statistical analyses were performed using the significance analysis of microarrays
(SAM) software package (Stanford University 22). This software utilizes an algorithm based
on the Student’s t-test to derive statistically significantly differentially expressed genes
between two groups of samples using a permutation-based determination of the median false
discovery rate (FDR). The SAM algorithm reports the FDR as the percentage of genes in the
identified gene list (rather than in the entire cohort of genes present on the microarray) that
are falsely reported as showing statistically significant differential expression. The threshold
of differential expression is adjusted to identify different sizes of sets of putatively
significant genes, and FDRs modified accordingly. The cutoff for significance in these
experiments was initially set at a FDR of <1% at a specified 1.1-fold change; stringent limits
that are reproducibly achieved using this platform.
Corroborative quantitative RT-PCR (qRT-PCR) analysis—The expression levels of
selected genes were analyzed by qRT-PCR. cDNA derived from reverse transcription of
DNAsed, total RNA from logarithmic growth phase glioma stem cell cultures primed with
oligo(dT) and random hexamers was used as the template for qRT-PCR analyses. All primer
sets were designed across intron-exon boundaries, and individual primer concentrations and
amplification conditions optimized for each gene. Dissociation curves were performed on all
reactions to assure product purity. Original input RNA amounts were calculated by
comparison to standard curves using purified PCR product as a template for the transcripts
of interest and were normalized to amount of H3.3 mRNA. The minimum expression level
of most genes detectable by qRT-PCR is approximately 1×10−8 pg, well below the limit of
detectability on the microarrays. Although no qRT-PCR was done in this pilot study, we
have designed primer pairs for over 300 transcripts selected from previous microarray
experiments. Using our stringent primer design algorithms, we have quantified the
expression 98–100% of these transcripts in a variety of tissues. In the majority of cases,
qRT-PCR directly corroborates the microarray data. However, at very low levels of
differential expression (around 12–18% difference, close to the limit of detection for qRT-
PCR), this level of corroboration between the two datasets is extremely difficult to achieve.
3.8. DISEASE LINK WITHIN CHROMOSOME 19
The “Disease Link” experiments will be generated by the comparison of well-annotated
samples obtained from patients matched to healthy control samples provided to the
Consortium by specialized clinics. Strategically it is the view of the C19C that these disease
link-related data are one of the most important deliverables that will be of high value and of
cardinal importance for generating added values to new drug development and novel
markers for diagnosing disease.
The goal for the outcome of the C19C initiative will consist not only of the Human
Proteome Sequence Map of the chromosome 19, but also to deliver future advances in
paradigms of disease understanding, new medical patient treatments, and tools for guiding
personalized medicine at the individual patient level in for example the treatments of cancer
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and cardiovascular diseases. It is anticipated that the future health care will require high-
density generated data-outs of both data and data comparisons in order to make accurate
diagnosis in patients for targeted personalized medicine. It is also anticipated that high-end
mass spectrometry sequencing and computational data-interpretation will be essential in the
proficient treatment of the ever-increasing number of patients in the world. Improved
understanding of the molecular alteration and mode of drug action in cancer cells in targeted
tumor tissues is fueling the future development of efficient patient drug treatments. The
future of biomedical sciences will be driven by the ability to adopt novel technologies,
which will generate petabytes of data (peta=1015) to understand the disease and develop new
treatments. This is especially relevant to diseases, such as cancer and cardiovascular
diseases, which carry a huge mortality and cost to global health care systems. Advances in
reducing mortality associated with these diseases are hampered by the lack of tools and data
for early detection, modeling of disease progression and evaluation of treatment response.
In addition to the indubitable academic interest of unraveling the chromosome 19 sub-
proteome it must be highlighted that nearly eighty human diseases and disorders have been
related to alterations of genes/proteins of chromosome 19 (Supplementary Table 5). These
diseases represent heterogeneous pathologies and effect many different organ systems,
represent both inherited and non-inherited, and occur at various points throughout life, from
congenital to childhood to late onset forms of clinical presentation.
Glioblastoma (GBM) is one such disease area that has been linked to aberrations in
chromosome 19 proteins. GBM is the most prevalent form of brain tumor. Despite advances
in chemotherapy and radiation treatments, the disease is nearly universally fatal. The
firsthand treatment is surgical brain tumor removal, followed by radiation and
chemotherapy. Despite reduction of the tumor size by 98% or more, recurrence is nearly
inevitable. Glioma cancer stem cells (GSCs) are hypothesized to provide a repository of
cells in GBM cell populations that can self renew and be refractory to radiation and
chemotherapeutic agents developed for the treatment of differentiated tumor cells. The
potential lack of response of GSCs to traditional cytotoxic and radiation therapies has
significant implications for tumor biology and therapeutics.
Scientists at the University of Texas M.D. Anderson Cancer Center (MDACC), Houston,
Texas, have isolated and genetically characterized forty-six GSC lines. All GSC lines have
been characterized with the expectation that assignment of these different lines will
potentially be classified according to previously described proneural, mesenchymal and
classical phenotypes 23. The mesenchymal subtype carries the poorest clinical prognosis, is
highly invasive and pro-angiogenic. The tumor cells have high mutation rates in NF1,
relatively fewer EGFR mutations and relatively lower EGFR expression. In contrast, the
classical subtype frequently carries increased copy numbers of the EGFR gene (chromosome
7), but TP53 (chromosome 17) mutations are unusual. Finally, proneural types have the best
prognosis and have high mutation rates in TP53, PDGFRA (chromosome 4) and IDH1
(chromosome 2).
3.9. POST-TRANSLATIONAL MODIFICATIONS
More than one hundred post-translational modifications (PTMs) of proteins have been
described and new types are still being discovered. Modifications of proteins by
phosphorylation, glycosylation, acetylation and ubiquitination have dramatic effects on
protein functions. Thus, any project that aims to assign protein function must take PTMs
into consideration. By searches of the chromosome 19 Uniprot identifiers in Protein
Information and Knowledge Extractor (PIKE, http://proteo.cnb.csic.es/pike) 24, roughly one-
third of chromosome 19 proteins were identified as phosphoproteins. This figure is likely to
grow once PTM characterization of chromosome 19 proteins is in an advanced stage of
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progress. The phosphorylation status of several chromosome 19 nuclear proteins was
determined in our study of GSC11 25. Two sites of serine phosphorylation (S299 and S300)
were detected on RNA polymerase II elongation factor ELL (P55199), three sites of
phosphorylation (S284, S288, S301) were determined on Nuclear factor 1 X-type (Q14938)
and four sites (S100, S103, S113, S114) on Transcriptional repressor p66-alpha (Q86YP4).
Furthermore, about 5% of the proteins were identified as known regulators of ubiquitination
and deubiquitination, and a large number of proteins were related to carbohydrate synthesis
and degradation.
In the context of the C19C project, two deliverables related to PTMs are implicated. First,
predicted functions of chromosome 19 proteins as kinases, glycosyltransferases etc., are
verified and second, the PTMs of each protein characterized. The analytical platform
includes enrichment, separation and tandem mass spectrometry. The choice of approach
requires optimization, even in the case of phosphorylation, which is a single chemical
entity26. The site localization and structural characterization of protein glycosylation is quite
complex, but essential to understand protein function in human health and disease.
Initially, the proteomes of each of the GSC cell line were characterized and quantified. The
transcriptomic and proteomic data will be correlated to determine the extent of chromosome
19 gene expression and coverage as a sub-proteome. Re-examination of an earlier
phosphoproteomic study by this group performed on GSC118 identified 148 proteins
encoded by chromosome 19 (Supplementary Table 4) out of >2,000 identified proteins. In
that study, a quantitative phosphoproteomic approach was employed that used enrichment of
phosphoproteins from differentially-treated GSC11 cells, chemical tagging with TMT6
reagents, separation by HILIC chromatography, metal-oxide-based enrichment of
phosphopeptides and tandem mass spectrometry. Those proteins were uploaded into
Ingenuity Pathways software and compared to the known proteins with association to
cancer. That analysis revealed that roughly one quarter of the GSC11phosphoproteins (34)
are associated with cancer.
3.10. BIOINFORMATICS OF CHROMOSOME 19 REPOSITORY
Gene expression profile data was mined to identify differentially expressed genes of
chromosome 19 from Gene Expression Omnibus (GEO) repository 27. From the top 1000
differentially expressed experiments a total of 285 genes were identified which were linked
to a cancer specific condition. The sub-set was further mined to identify 64 genes which are
clustered based on proximity on chromosome 19, and mapped to specific locations on the
chromosome as show in Figure 8.
The IT infrastructure is crucial in order to allow all the research teams to interact and
collaborate with clinical patient samples as well as biological samples where the sample-,
and data sharing can be made in an efficient way in agreement with the highest ethical
standards. Within the consortium we have developed an IT-infrastructure, utilizing FDA
approved software for sample and data processing, as well as the link to clinical proteomic
units, at three hospitals/universities, and with national biobank units.
The structure of the LIMS is built with an interactive module operation that allows any
sample to be processed at any time point by multiple research teams. The LIMS will be
tracking all time points that relates to sample processing and data file generation. The
samples are all handled by 2D barcoding systems, where each research team uses their
respective scanners when samples are analyzed.
There will be several data categories generated, such as the archiving of samples, that
hierarchically are assigned to the patient identifier, that is related to the sample type e.g.,
Nilsson et al. Page 14
J Proteome Res. Author manuscript; available in PMC 2014 January 04.
$watermark-text
$watermark-text
$watermark-text
tissue (type), blood fractions (EDTA, heparin and/or citrate) plasma, serum or whole blood,
or any target cells isolated from blood or tissue samples. In addition, data categories will be
built by linking each biobank sample to data file generation. This data management
architecture system will be utilized by each research team within the Chromosome 19
Consortium, and we believe that the strategy and experience of data managements will bring
extremely valuable overall structure to our research groups.
The LIMS unit in Lund is functioning as the hub and provides resource for participating
groups to gather and harmonize acquired data, which is sorted and shared on the repository
server. The network and links in-between the chromosome 19 research teams is depicted in
(Supplementary Figure 2) that ensures an efficient and real-time access to the Chromosome
19 Database. Our IT structure allows us to work across research teams and interact on a
daily basis where some of our teams are data generating with mass spec protein sequencing
or protein quantitation files, while others are assigned to make statistical analysis. The IT
infrastructure also allows analysis files to be copied and evaluated by other teams with an
interactive work process. We have developed a work flow that manages all the data
generation and curation to a final point where the bioinformatics team will be responsible to
align with the C-HPP repository, and post all the chromosome 19 data, making them
publicly available.
4. CONCLUSIONS
The C-HPP represents a dedicated and high-level attempt to relate human disease to specific
gene expression and protein expression to loci present on the 23 pairs of human
chromosomes. In this report the Chromosome 19 Consortium provides insight into its
strategy and work platforms to discover what relationships exist between specific
phenotypes of disease and the allelic forms of genes located on chromosome 19. Our
research teams have developed transcript and protein microarray platforms that is used as a
complement to the MRM quantitation capability and the antibody library, where the
synergistic effects will be optimized to deliver value to the C-HPP repository as a global
open access resource. These efforts at the start of our joint chromosome 19 project are in
line with the C-HPP guideline 28. We have established a collaborative consensus within our
consortium, where we have introduced respective responsible research tasks, associated with
experimental approaches, including data production with quality control. The curation of
data has been multi-tasked and processed in-between continents with resulting collaborative
benefits. We also identified compelling gene sequences in human diseases such as cancers
that will be mandatory in our search for the right biological material to identify the missing
proteins. Similar investigations on all the other human chromosomes will result in a new
understanding of human biology and new knowledge regarding possible targets of medical
intervention to limit disease development. Along the way, many new ways of working with
mega-data packages and analysis tools will also need to be obtained and validated
throughout the community. The research, and healthcare societies will also need to support
the development of integration systems that allows for standardization of sample collection
and storage, search routines on sample collections, and as well as data sets of annotated
clinical data that has been generated from these cohorts. In the end of the day, both the C-
HPPs, as well as other global research activities are looking for tools that can bridge the data
and deliverables that will be of major use in future drug development and patient treatments.
Unifying the different disciplines will aid in the fulfilling of the aspiration provided in the
concepts of personalized medicine and systems biology.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Illustration of the elements and workflow that will form the basis for the objectives and
goals within the Chromosome 19 Consortium.
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Figure 2.
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Identification of proteins by using (A) UniProt (version 2012_04 April 18, 2012) and (B)
neXtProt database (version 2012_04_10). Localization (C) and functions (D) of proteins
presented are based on database search in PRIDE.
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Figure 3.
Schematic illustration of the workflow applied within the pilot study.
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Figure 4.
The results from the comprehensive MS analysis of synthetic peptides used in the Pilot
Study.
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Figure 5.
Categories of the MRM results illustrated by selected examples.
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Figure 6.
Illustration of the biobanking workflow (A). Selected MRM transitions of the signature
peptides of PSA (B). PSA 3D structure with indication of the tryptic peptides used for
identification (C).
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Figure 7.
Schematic overview of the workflow status of Chromosome 19 genes.
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Figure 8.
Clustering of chromosome 19 genes differentially expressed in breast cancer, prostate
cancer, lung cancer, brain cancer and leukemia.
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Table 1
Genomic data of chromosome 19
Length (bps) 59,128,983
Known Protein-coding Genes 1400
Novel Protein-coding Genes 18
Pseudogene Genes 180
miRNA Genes 110
rRNA Genes 13
snRNA Genes 29
snoRNA Genes 31
Miscellaneous RNA Genes 15
SNPs 987,809
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